OncoMatch/Clinical Trials/NCT06132503
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Is NCT06132503 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LP-284 for relapsed or refractory lymphomas.
Treatment: LP-284 — The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Allowed: BCL2 rearrangement
Allowed: BCL6 rearrangement
Allowed: MYC rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care treatment
relapsed from or is refractory to at least two prior standard of care treatments or tumors for whom standard therapies are not available
Cannot have received: allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplant
Cannot have received: autologous hematopoietic stem cell transplant
Exception: within 6 months prior to first dose of study drug or patient has progressed within 6 months from the day of stem cell infusion
Autologous hematopoietic stem cell transplant within 6 months prior to first dose of study drug or patient has progressed within 6 months from the day of stem cell infusion
Cannot have received: radiation therapy
Exception: within 4 weeks prior to the first dose of study drug, unless the tumor site continues to increase in size after the patient has completed radiotherapy treatment
Radiation treatment within 4 weeks prior to the first dose of study drug, unless the tumor site continues to increase in size after the patient has completed radiotherapy treatment
Cannot have received: major surgery requiring general anesthesia
Exception: within 4 weeks prior to the first dose of study drug
Major surgery requiring general anesthesia within 4 weeks prior to the first dose of study drug
Cannot have received: live vaccine
Exception: within 1 month prior to the first dose of study drug
Received live vaccine within 1 month prior to the first dose of study drug
Cannot have received: investigational or non-investigational anti-cancer therapy
Exception: within 2 weeks or within at least 5 half-lives (up to a maximum of 4 weeks from any biologics/immunotherapies) prior to the first dose of study drug, whichever is shorter
Exposure to investigational or non-investigational anti-cancer therapy within 2 weeks or within at least 5 half-lives (up to a maximum of 4 weeks from any biologics/immunotherapies) prior to the first dose of study drug, whichever is shorter
Lab requirements
Blood counts
ANC ≥ 1500/μL (Phase 1b: ANC ≥ 1000/μL if documented by investigator as the normal baseline for the patient); Hemoglobin ≥ 8 g/dL (for those patients undergoing RBC transfusion, hemoglobin must be evaluated after at least 14 days after the last RBC transfusion); Platelet count ≥ 100,000/μL (assessed ≥ 7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets). (Phase 1b: ≥ 75,000/μL may be acceptable after discussion with the Sponsor)
Kidney function
Serum creatinine clearance ≥60 mL/min, either measured or calculated using standard Cockcroft-Gault formula; serum electrolyte (potassium, calcium, and magnesium) levels within the normal reference range (may be supplemented according to institutional standards)
Liver function
AST, ALT ≤ 3x ULN or < 5x ULN in cases of documented lymphoma involvement of liver; total serum bilirubin ≤ 1.5 x ULN or < 5x ULN if secondary to Gilbert's syndrome or documented lymphoma involvement of liver
Cardiac function
No ongoing unstable cardiovascular function (symptomatic ischemia, uncontrolled clinically significant conduction abnormalities, congestive heart failure NYHA Class ≥ III, myocardial infarction within 3 months prior to Screening); No congenital long QT syndrome or QTcF ≥ 470 ms (except for bundle branch block or pacemaker, with discussion with Medical Monitor)
Adequate organ function at Screening and on C1D1 (pre-dose) defined as: Liver Function ... Renal Function ... Bone Marrow Function ... Ongoing unstable cardiovascular function ... Congenital long QT syndrome, or a QT interval corrected by Fridericia's formula (QTcF) ≥ 470 ms ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cancer and Blood Specialists Clinic · Los Alamitos, California
- Florida Cancer Specialists · Lake Mary, Florida
- SCRI Oncology Partners · Nashville, Tennessee
- START Mountain Region · West Valley City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify